Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TABFAT: Tirzepatide in Obesity
NCT06893211Phase 2Completed
- Sponsor
- University Medical Centre Ljubljana
- Start
- Mar 2025
- Primary completion
- Nov 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in obesity comparing Tirzepatide with Placebo (2 arms). Primary endpoints: Change in Brown Adipose Tissue Activity and Volume at 24 weeks and Change in Molecular Markers of Browning in Subcutaneous White Adipose Tissue at 24 weeks. Started Mar 2025; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06893211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06893211.